A large number of glycoprotein (GP) Ilb/llla receptors are present on the surface of platelets. Studies to define precisely the number of GPllb/llla receptors using specific monoclonal antibodies (MoAbs) or fibrinogen binding have, however, yielded varying estimates of receptor number. To refine the quantitative estimation of GPllb/llla receptors on resting platelets, we have used the MoAb 7E3, which has high affinity for GPllb/llla. Quantitative binding studies were performed using radiolabeled conjugates of 7E3 IgG, as well as fragments and derivatives of 7E3. For platelets obtained from any single individual, the numbers of 7E3 F(ab'), and IgG molecules bound per platelet were equivalent (-40.000). whereas the number of Fab molecules bound per platelet was consistently approximately twofold higher (-80,000).
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To investigate the basis of the quantitative disparity in bind-
HE PLATELET surface is densely populated with re-T ceptors for adhesive protein ligands.' Most prominent among these receptors is the glycoprotein IIbAIIa complex (GPIIbAIIa). An accurate assessment of the number of surface GPIIbAIIa receptors is important for understanding the normal and pathological responsiveness of platelets. The GPIIbAIIa receptor on resting platelets does not bind ligands with high affinity; after activation, the receptor develops a high binding affinity for fibrinogen and other adhesive proteins that enables the receptor to cross-link platelets one to another in stable platelet aggregates.' Approximately 40,000 fibrinogen molecules have been reported to bind per activated platelet,3-' but this cannot be directly translated into receptor number because fibrinogen is dimeric and has a total of six regions that may potentially interact with GPIIb/ IIIa receptors. Studies of the binding of small monovalent agents such as peptides and snake venom proteins6-* to GPIIbAIIa have yielded varying estimates of the number of molecules bound per platelet which may reflect differences in binding affinities or other properties. Monoclonal antibodies (MoAbs), by virtue of their high affinity and specificity for GPIIbAIIa and the similarity of results using different antibodies, have been considered the most reliable indicators of GPIIbLIIa copy number.
Regardless of the antibody used, a range of 35,000 to 50,000 antibody molecules have been reported to be bound per with approximately a twofold variability in the number of receptors present on platelets from different individual^.'^ Our previous studies with antibody 7E3" and studies by others using different anti-GPIIbAIIa MOA"'^, '' indicated that more Fab' molecules bound per platelet than intact IgGs or F(ab'), fragments of the same antibodies. Various mechanisms can be proposed to explain these observations, among which are: (1) the existence of unique receptor pools that are accessible only to Fab fragments and not to IgGs, based on size-dependent access, (2) steric interference caused by the binding of another antibody molecule to an adjacent GPIIbAIIa receptor, (3) internalization of Fab molecules into platelet a-granules, with perhaps binding to GPIIb/ IIIa receptors in the a-granule membrane, (4) recruitment of GPIIbAIIa receptors to the platelet surface from the a-granule pool triggered specifically by Fab fragments, or (5) simultaneous binding of the bivalent antibody species [IgG and F(ab')'] to two different GPIIbAIIa receptors. To differentiate between these mechanisms, we have studied the binding to platelets of 7E3 IgG, F(ab')', and Fab, as well as a newly constructed, bispecific (Fab' )' molecule containing only a single 7E3 combining site, but having the same size as 7E3 F(ab' )2.
MATERIALS AND METHODS

Chemicals and reagents.
Abbreviations.
All chemicals were purchased from commercial sources and used without purification.
Purified antibody fragments of IgG are defined as follows: Fab denotes the IgG fragment produced by papain digestion, comprised of a light chain linked to the proteolytically cleaved heavy chain, and functionally monovalent for antigen binding; F(ab'), is a functionally bivalent fragment, a dimer of two Fab' fragments and is produced by pepsin digestion of IgG; Fab' is a monovalent fragment derived by mild reduction of the F(ab'), fragment followed by alkylation with iodoacetamide to prevent reoxidation of the sulfhydryl residues"; (Fab' )2 designates a bivalent fragment obtained by chemical or oxidative reconstitution of two Fab' fragments; a bispecific (Fab' )z fragment is reconstituted from two different Fab' fragments.
The intact 7E3 and the 7E3 fragments bind to platelet GPIIbnIIa and also to the vitronectin receptor. The murine 7E3,I6 the murinehuman chimeric 7E3,2' and OC125 (anti-ovarian cancer antigen)" MoAbs were produced from hybridoma cell lines. The intact IgG molecules were isolated from cell supernatant by
MoAbs.
affinity chromatography on Protein A-Sepharose (Pharmacia, Uppsala, Sweden). The Fab fragments were prepared by papain digestion and the F(ab' )2 fragments were prepared by pepsin digestion." The fragments were further purified on Protein A-Sepharose to remove Fc-containing materials, and/or other gel filtration and/or ion exchange chromatography procedures to remove other contaminants. The OC125 Fab' fragment was prepared by mild reduction of the corresponding F(ab' )z fragment followed by alkylation with iodoacetamide to prevent reoxidation of the disulfide bonds. The murine 7E3 Fab and the humanlmurine chimeric 7E3 Fab (ReoPro, abciximab; Centocor, Malvern, PA) fragments which are essentially identical in platelet binding and platelet function inhibition properties,21 were used interchangeably in these experiments, and are collectively identified as 7E3 Fab. The 7E3 IgG and the OC125 and 7E3 F(ab')2 fragments used in these analyses were the native murine molecules.
The method of preparation of the bispecific 7E3XOC125 (Fab')2 fragment was the same used to prepare the bispecific 7E3xP4B6 (Fab'), fragment.24 Briefly, parental F(ab')? fragments of an antibody to a cancer antigen not present on platelets, OC125, and 7E3 were reduced in 20 mmol/L L-cysteine and then the L-cysteine was removed by gel filtration. The reduced Fab' fragments were coupled using bis-maleimido methyl ether (BMME). Any remaining free sulfhydryl groups were capped with 5,5 dithiobis-(N, N')-nitrobenzoic acid, then the mixture was treated again with L-cysteine to reduce any recombined, non-BMME linked, parental (Fab' ), fragments, and gel filtered using Sephacryl S-100 (Pharmacia) to remove the Fab' fragments. The bispecific species was resolved from the recombined, cross-linked parental molecules using hydrophobic interaction HPLC with a TSK phenyl-5-PW column (Bio-Rad, Hercules, CA). As a control, the BMME linking process was repeated using 7E3 Fab' for both arms of the recombined 7E3 (Fab'), molecule.
Estimation @antibody concentrations. Antibody concentrations (milligrams per milliliter) were assigned by dividing the absorption at 280 nm by 1.4.*' Molecular weights were estimated for the 7E3 IgG, OC125 F(ab'),, OC125 Fab', and the bispecific 7E3XOC125 (Fab'),; and assigned based on the amino acid composition for the 7E3 Fab, 7E3 F(ab')z and the reconstituted 7E3 (Fab'), fragments. Molecular weights used were: 7E3 Fab = 47,600; 7E3 IgG = 150,000; OC125 F(ab')> = 100,000; OC125 Fab' = 50,000; bispecific 7E3xOC125 (Fab'h = 100,000; 7E3 F(ab')2 = 97.600; reconstituted 7E3 (Fab'), = 97,600.
Antibodies were iodinated using a modification of the Iodogen methodZh to a specific activity of 1 to 3 fiCi/pg. Briefly, 90 p g of antibody was incubated with 0.5 mCi of Nal"l (Amersham Corp, Arlington Heights, IL) in tubes precoated with 5 pg of Iodogen (Pierce, Rockford, IL) for 5 minutes at room temperature. The reaction was halted by the addition of 5 "0% ascorbic acid and removal of the incubation mixture from the reaction vial. Free iodine was removed by gel filtration on a PD-IO column (Pharmacia). Antibodies were diluted with unlabeled antibody to achieve desired specific radioactivities.
The monomeric nature of the iodinated antibody molecules and fragments was confirmed using gel filtration chromatography. The 7E3 Fab, F(ab'), and IgG molecules were subjected to a mock iodination using cold sodium iodide under comparable conditions used to radiolabel these same molecules. The gel filtration retention times of the cold I-labeled antibody and antibody fragments were analyzed using a Bio-Rad Bio-Si1 SEC 250 column (300 X 7.8 mm) with a mobile phase of 0.2 m o m sodium phosphate, pH. 6.8 at a flow rate of I .O mL per minute. The retention times of the unlabeled 7E3 Fab. 7E3 F(ab')Z and 7E3 IgG molecules were identical to those of the corresponding I-labeled molecules (retention times of 9.64, 8.36, and 7.86 minutes, respecPreparation of chemically cross-linked (Fab' ), fragments.
Radioiodination ofproteins.
Gel $itration chromatography. tively), indicating that none of these antibody molecules aggregated as a result of radioiodination.
Blood donors were selected from normal healthy adult volunteers who had not taken aspirin or an antihistaminic for a minimum of IO days. Whole blood was drawn by venipuncture into 1: 100 final volume of 40% trisodium citrate, and centrifuged at 600g for 6 minutes (or equivalent) at 22°C for preparation of platelet-rich plasma (PRP). For some experiments, platelets were isolated from the plasma by gel-filtrati~n~' of PRP on Sepharose 2B-C1 (Pharmacia) pre-equilibrated in modified Tyrode's buffer containing 20 mmoUL HEPES, pH 7.5, 187 mmol/L NaCI, 4 mmol/L KC1, 50 mmom NaZHPO4, 1 mmollL MgCI,, 5.5 mmol/L glucose. and 2% bovine serum albumin. PGE, (final concentration 1 nmol/ L) was added to the gel-filtered platelet suspensions and the platelets were allowed to incubate at room temperature for at least 30 minutes before the initiation of binding studies. Platelet counts of the PRP and gel-filtered platelets were determined using a resistance particle counter (Coulter ZM, Hialeah, FL). Platelet counts of the PRP were adjusted to 300,000 t 50,000 platelets/pL with autologous plateletpoor plasma if necessary.
A direct binding method" wah used for measuring the number of antibody and antibody fragment molecules able to bind to platelets in both PRP and gel-filtered platelet suspensions. PRP was incubated with 'zsI-labeled antibody or fragment for 30 to 60 minutes at room temperature. Replicate (3) 100-pL aliquots of the PRP were then centrifuged through 200 pL of 30% sucrose to separate free from platelet-bound antibody. The number of molecules of antibody bound per platelet was calculated as: the fraction of the total radioactivity that was platelet bound X the total antibody content (fig) X the appropriate conversion factor to obtain molecules per pg [Avogadro's number divided by (the antibody molecular weight x 10" pg/g)], divided by the number of platelets in the sample.
Rate of dissociation of radiolabeled 7E3 Fab and F(ab')? from platelets. Studies were performed by first incubating a subsaturating amount of IZ5I-7E3 Fab (0.2 MglmL) or I2'I-7E3 F(ab'), (0.2 pgl mL) with PRP for 30 minutes at 37°C and determining the amount of radiolabeled antibody bound. Antibody dissociation was initiated by the addition of a 100-fold excess (20 pg/mL) of unlabeled 7E3 Fab or F(ab'), to the incubations containing 1251-7E3 Fab or 7E3 F(ab')z, respectively. The amount of bound radioactivity was determined following separation of the platelet-bound fraction from the unbound antibody fraction by centrifugation through 30% sucrose (described above). Platelet-bound radioactive antibody was determined at various time points up to 5 hours after the addition of unlabeled antibody and expressed as a percentage of the initial amount bound.
A two-step assay was developed to assess the effect of prior exposure of platelets to various antibodies on the ability of I2'1-7E3 Fab to bind in a subsequent incubation step. PRP was first incubated with unlabeled antibodies at 10 pg/mL for 60 minutes at 22°C. In the second step, 12s1-7E3 Fab was added to a final concentration of 15 pg/mL, and incubated for an additional 30 minutes at 22°C. Quantification of bound radiolabeled antibody was performed as described above for the direct platelet binding assay.
The binding of "'I-7E3 IgG or "'1-7E3 Fab to gel-filtered platelets was determined after stimulation with a-thrombin (Enzyme Research Laboratories, South Bend, IN), according to the procedure of Lombardo et al.'* Aliquots of gel-filtered platelets were incubated with either 0.1 U/mL of thrombin or an equivalent volume of Tyrode's buffer for 10 minutes at 22 to 25°C. Hirudin (Sigma, St Louis, MO) was then added at a 16-fold excess (UIIT) and allowed to incubate 
Sequential saturation platelet binding assay.
Binding of antibody to thrombin-stimulated platelets.
For personal use only. on January 14, 2018. by guest www.bloodjournal.org From for 5 minutes at room temperature to neutralize the thrombin. Binding studies were then performed as described above.
GPIIbAUa was purified from outdated human platelets (50 to 100 U) obtained from the American Red Cross (Penn-Jersey Region, Philadelphia, PA). The platelets were pelleted, washed in 20 mmoVL Tris-CI, 150 mmom NaCI, 0.4% sodium citrate, pH 7.0 buffer, and pelleted again. The GPIIb/ IIIa was extracted by stirring overnight at room temperature in 1% Triton X-100, 20 mmol/L Tris-C1, 150 mmoVL NaCI, 1 mmoVL CaCI,, lo-' mol/L leupeptin, pH 7.4. The platelet fragments were separated from the soluble GPIIblIIIa by centrifugation and filtration. The filtered supernatant was applied to an affinity column containing 10E5 (anti-GPIIblIIIa MoAb) IgG. The bound GPIIblIIIa was eluted with 50 mmollL diethanolamine, 0.1% Triton X-100, 1 mmoVL CaCI,, pH 1 1.5. The eluted GPIIblIIIa was immediately neutralized with 2 moVL Tris-C1, 10 mmol/L CaC12, pH 7.0. The GPIIblIIIa was concentrated in a stirred cell ultrafiltration device and stored with 0.1% sodium azide at 4°C. The GPIIblIIIa purity and activity was assessed using nonreducing and reducing gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), high-performance liquid chromatography gel filtration analysis, immunoblots, and binding of 7E3 and 10E5 antibodies in an enzymelinked immunosorbent assay (ELISA). The isolated GPIIblIIIa receptor exhibited approximately 98% purity by the gel filtration analys~s , *~ with some minor contaminants observed by SDS-PAGE and immunoblot analyses.
The binding of the native murine 7E3 F(ab'),, the recombined 7E3 (Fab'),, and the bispecific 7E3xOC125 (Fab'), to purified GPIIblIiIa was evaluated in a coated-plate
The assay compared half-maximal binding concentrations of twofold dilutions of the 7E3 and OC125 fragments (evaluated from 1 to 1,000 nglmL) to purified GPIIblIUa, which was detected using a peroxidase-conjugated, murine F(ab' ), fragment-specific, goat antibody.
The 7E3 F(ab'),, OC125 Fab', OC125 F(ab'),, and 7E3xOCI25 (Fab'), molecules were analyzed for the ability to inhibit binding of OC125 IgG (anti-ovarian cancer antigen) in a CA 125 radioimmunoassay (RIA) (Centocor). The CA 125 RIA was a simultaneous, sandwich immunometric assay that used a single antibody, OC125, as both capture and signal antibody using anti- To further investigate the difference in binding of 7E3 F(ab'), and 7E3 Fab to platelets, the rates of dissociation of each fragment were compared. Dissociation of plateletbound, "'I-7E3 F(ab'), and 12'II-7E3 Fab was measured after addition of a 100-fold excess of the respective unlabeled antibody as shown in Fig 4. The I2'I-7E3 F(ab'), dissociated from platelets much slower than did I2'1-7E3 Fah under these conditions. After 5 hours of incubation with the competing unlabeled 7E3 F(ab')z, 96% of the I2'I-7E3 F(ab'), remained bound to platelets. Only 42% of the "'1-7E3 Fab remained bound after the same interval. The significantly slower dissociation of 7E3 F(ab'), is consistent with it binding to two different GPIIb/IIIa receptors simultaneously.
Studies to assess whether 7E3 Fab can bird to a subpopulation of GPlIb/lllu receptors inaccessible to 7E3 IgG and 7E3 F(&)z. To assess whether all forms of 7E3 have equal accessibility to the same population(s) of GPIIblIIIa recep-WAGNER ET AL
tors, a two-step binding experiment was designed. If the larger, bivalent 7E3 molecules could not access certain GPIIb/IIIa receptors that the smaller 7E3 Fab fragments could engage, then radiolabeled 7E3 Fah should be able to bind to platelets pretreated with 7E3 IgG. In the first step, aliquots of PRP were preincubated for 1 hour with I O pg/ mL of 7E3 Fah, 7E3 F(&'),, 7E3 IgG, or a non-plateletspecific control antibody, OC125 F(ab'),. In the second step, Iz5I-7E3 Fab (15 pg/mL) was added, and the incubation was continued for an additional 30 minutes. The rates of dissociation of 7E3 IgG" and 7E3 F(ab'), (Fig 4) from the platelet surface are slow, ensuring that antibody that bound to the platelets in the preincubation step would not dissociate significantly in the subsequent 30-minute incubation step.
The results shown in (Table 1) . Thus, these data do not support either of the hypotheses that the twofold increase in 7E3 Fab binding compared to 7E3 IgG is due to unique activation of platelets by 7E3 Fab or to unique access of 7E3 Fab to the internal pool of GPIIbDIIa present in unactivated platelets.
Studies of the effect of molecular size and valency using the bispecgc 7E3XOC125 (Fab')2 molecule. A bispecific antibody with the size of an F(ab'), fragment but with only a single binding site for GPIIbmIa was synthesized. To ensure that the activity of the chemically cross-linked bispecific (Fab'), molecule was comparable to the native 7E3 F(ab')2, it was evaluated in a GPIIb/IIIa binding ELISA. The native 7E3 F(ab'),, the recombined 7E3 (Fab'),, and the bispecific 7E3xOC125 (Fab'), had comparable half-maximal GPIIb/ IIIa binding concentrations, whereas the native OC 125 F(ab'), had no activity over the concentration range tested (data not shown). If antibody size is the major factor defining the number of 7E3 molecules bound, then the binding of the 7E3xOC125 (Fab'), should parallel that of the 7E3 F(ab'),.
If valency is the determining factor, then the bispecific (Fab')2 molecule should bind to the same extent as 7E3 Fab, since the OC125 combining site does not recognize GPIIW IIIa.
The binding of the bispecific 7E3xOC125 (Fab'), antibody and a control, reconstituted bivalent 7E3 (Fab' )2 fragment were tested against the platelets obtained from the same 7 donors used for the experiment described in Fig 3. As shown in Fig 6, the binding of the bispecific (Fab'), (76,800 ? 6,300 molecules per platelet) was similar to the binding of the 7E3 Fab (81,000 2 9,200 molecules per platelet) (Fig  3) , and both were significantly greater than the binding of native 7E3 F(ab'), (43,400 2 5,900 molecules per platelet) (Fig 3) or the reconstituted 7E3 (Fab'), (38,500 t 4,200) (Fig 6) . The similarity in binding properties of the native 7E3 F(ab'), and the reconstituted 7E3 (Fab'), indicates that The number of radiolabeled 7E3 IgG or 7E3 Fab molecules bound per platelet was quantified using platelets from normal donors in both PRP and after gel filtration to remove fibrinogen. The binding of "'l-7E3 IgG or '"1-7E3 Fab was also measured using gel-filtered (GF) platelets after the platelets were stimulated for 10 minutes with thrombin (0.1 U/mL). All platelet samples were then incubated with the radioiodinated forms of 7E3 for 30 minutes at room temperature. After the separation of platelets from the unbound 7E3 molecules by centrifugation through 30% sucrose, the number of platelet-bound lZ51-7E3 molecules were quantified. The numbers represent the average of 5 determinations 5 1 SD.
For personal use only. on January 14, 2018. by guest www.bloodjournal.org From the BMME linkage procedure does not significantly alter the binding properties of 7E3. The nonspecific binding of radiolabeled OC125 F(ab')2 control antibody fragment was 400 t 200 molecules per platelet. Thus, the results with the bispecific 7E3XOC125 (Fab'), fragment indicate that the valency rather than the size of the 7E3 species determines the extent of binding to platelets.
DISCUSSION
Investigations designed to establish the number of cellular antigens or receptors routinely rely on quantitative determinations of ligand or specific MoAb binding. Quantitative evaluation of the binding of the ligand fibrinogen to the platelet as a method of estimating the number of GPIIbOIIa receptors on the surface of unactivated platelets has serious limitations because (1) activation stimuli may not result in all GPIIb/IIIa receptors undergoing the transition to the high affinity ligand binding state, (2) the binding of one fibrinogen molecule may result in steric hindrance that limits the binding of other fibrinogen molecules, (3) internal pools of GPIIbnIIa may join the surface, and (4) the stoichiometry of fibrinogen binding to GPIIb/IIIa may not be 1 : 1.
MoAbs and fragments of MoAbs that bind to the unactivated form of GPIIbfiIIa should, in theory, provide a more direct means for assessing receptor number on unactivated platelets, but issues of steric hindrance, access to internal stores, and the stoichiometry of binding may also affect the results. The consistent observation by US'* and others'"'" of a larger number of Fab or Fab' fragments binding per platelet than intact IgG molecules requires a rigorous examination if one is to obtain an accurate estimate of the numbel of platelet surface GPIIb/IIIa, and that is why the current studies were undertaken. We exploited the high-affinity binding properties of the 7E3 MoAb to GPIIb/IIIa receptors on both unactivated and activated platelets, and the ability to make a variety of forms of the 7E3 antibody differing in size and valency. Although the rate of 7E3 F(ab')? and 7E3 Fab fragment binding to unactivated platelets is more rapid than observed for the larger IgG molecule,'* maximal platelet binding for all 7E3 molecules is obtained rapidly at concentrations of 5 ,ug/mL. For the present studies, binding incubations were performed for 30 to 60 minutes to ensure that equilibrium binding was attained. Previous studies established that the equilibrium dissociation constants for the interaction of 7E3 IgG, F(ab'), and Fab to resting platelets are similar at 4 nmol/L, 2 nmol/L, and 5 nmol/L, respectively (data not shown). Except for the experiments that required gel-filtered platelets, all other binding studies were conducted in PRP that was prepared from freshly obtained, citrate-anticoagulated blood from donors who had not taken antiplatelet agents.
In addition to platelet GPIIb/IIIa, 7E3 also binds to another integrin receptor, that also contains the GPIIIa (p3) subunit. Although a,p3 is present on platelets, the number of a,p3 receptors is very small (-50 to 200 per platelet) representing less than 0.5% of the number of GPIIb/IIIa receptors.'2 Thus, the potential contribution of platelet a,pl to total 7E3 binding was disregarded for these quantitative binding studies.
The results of this study indicate that the most plausible explanation for the twofold higher binding of 7E3 Fab compared with 7E3 IgG is that each of the two antibody-combining sites of the 7E3 IgG engages a separate and adjacent GPIIbDIIa molecule. Several lines of evidence are consistent with this explanation. No evidence was found to support the existence of discrete surface GPIIb/IIIa receptor populations that are accessible only to the Fab fragment and not to F(ab')* or IgG. Thus, exposure of platelets to saturating concentrations of unlabeled 7E3 IgG or F(ab')? blocked the access of 7E3 Fab to the platelet surface nearly as well as did unlabeled 7E3 Fab. No evidence was obtained to suggest that the 7E3 Fab fragment produced release of a-granule contents or increased surface GPIIb/IIIa expression.
Moreover, it is unlikely that selective internalization of 7E3 Fab accounts for the differences in binding because the number of molecules of 7E3 Fab that bound to platelets increased when platelets were preactivated with thrombin, to approximately the same extent as did platelets reacted with 7E3 IgG. It is also unlikely that the larger molecular size of the 7E3 IgG or F(ab'). fragment i s responsible for limiting the extent of binding to one half the leve) of the 7E3 Fab fragment because the bispecific 7E3xOC125 (Fah')? fragment, containing only one 7E3 combining site, bound to platelets to the same extent as 7E3 Fab, ie, twice the level of 7E3 (Fab')?. This result establishes that size alone is not a major determinant of the extent of binding and points, instead, to a bivalent mode of binding of IgG and F(ab')? fragments to surface GPIIb/IIIa as explaining the twofold disparity in binding. The results are most consistent with a bivalent binding of 7E3 IgG or F(ab')? to two adjacent receptors on the same platelet, because IgGs are ineffective at bridging between platelets" and no evidence of agglutination was 
